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Abstract
BothHIV disease and frailty syndrome are risk factors for neurocognitive impairment. Longitudinal research among individuals of the
general population suggests that frailty predicts future cognitive decline; however, there is limited evidence for these longitudinal
relationships among people living with HIV (PLWH). The current study evaluated and compared rates of cognitive decline over 2
years among HIV serostatus and frailty status groups. Participants included 50 PLWH and 60 HIV-uninfected (HIV−) participants
who were evaluated at baseline and 2-year follow-up visits. Baseline frailty status (non-frail, pre-frail, and frail) was determined using
fried frailty phenotype criteria. Neurocognitive functioning was measured using practice-effect corrected scaled scores derived from a
comprehensive neuropsychological battery covering seven cognitive domains. Repeated measures analysis was used to estimate rates
of global and domain-specific cognitive change from baseline to 2-year follow-up among each of six HIV/frailty status groups.
Among PLWH, the pre-frail group demonstrated consistent declines in global cognitive functioning (B = − 0.029, p = 0.034),
processing speed (B = − 0.047, p = 0.031), and motor functioning (B = − 0.048, p = 0.038). Among HIV− participants, pre-frail
individuals also declined in global cognitive functioning and processing speed (ps ≤ 0.05). HIV− non-frail participants also declined in
the cognitive domains of learning, delayed recall, and motor functioning; however, these declines appeared to be driven by relatively
higher baseline scores among this group. Notably, 38% of PLWH changed in frailty status from baseline to follow-up, and those with
stable pre-frailty demonstrated higher likelihood for cognitive decline; change in depressive symptoms did not relate to change in
frailty status. Current findings highlight pre-frailty as an important clinical syndrome that may be predictive of cognitive decline
among PLWH. Interventions to prevent or reduce frailty among vulnerable PLWH are needed to maintain optimal cognitive health.
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Introduction
Individuals aged 65 and older are estimated to compose 20%
of the US population in the next decade (Bureau, 2018).
Within this same period, due to significant advancement in
treatment success, it is estimated that 3 out of 4 people living
with HIV (PLWH) will be 50 and older (Smit et al., 2015). As
the demographic of both the general population and PLWH
ages, preservation of independence and improving overall
quality of life in this rapidly aging population is becoming
an essential focus of research.
Despite complete viral load suppression and immune re-
covery among PLWH, this population remains more vulnera-
ble to adverse aging-related health conditions compared to
individuals without HIV (Deeks, 2011, Guaraldi et al., 2001,
Greene et al., 2015). In particular, PLWH appear to exhibit
greater severity of frailty syndrome than uninfected individ-
uals, and frailty also contributes to worsened health outcomes
among PLWH (Brothers et al., 2014). Frailty is most widely
accepted as a common physiological syndrome characterized
by decreased reserve and diminished resistance to stressors,
resulting in a cumulative decline across multiple physiological
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systems and causes vulnerability to adverse outcomes
(Ferrucci et al., 2004). Frailty has increased prevalence with
advanced age and carries an increased risk for adverse health
outcomes, including depression, decreased ability to self-care,
poorer quality of life, and mortality (Fried et al., 2001,
Vaughan et al., 2015, Slaets, 2006, Rizzoli et al., 2013,
Erlandson et al., 2014). Frailty is also independently associat-
ed with HIV (Kooij et al., 2016) and may be present in up to
half of older adults living with HIV (Onen et al., 2010).
Together, the combined effect of HIVand frailty may amplify
and compound HIV disease burden and subsequently de-
crease the ability to remain independent in later life.
Furthermore, both frailty and HIV are independently linked
to cognitive impairment, a robust contributor to decreased in-
dependence and poorer quality of life among those with and
without HIV (Heaton et al., 2004a, Oppenheim et al., 2018).
Current understandings of frailty and cognition suggest that
their relationship is bidirectional. For instance, longitudinal
studies among the general population of older adults suggest
that frailty status predicts cognitive decline (Godin et al., 2017,
Auyeung et al., 2011, Mitnitski et al., 2011, Lee et al., 2018,
Brigola et al., 2017) and incident dementia (Boyle et al., 2010a,
Gray et al., 2013, Buchman et al., 2007) and also that cognitive
decline is predictive of the development of frailty syndrome
(Raji et al., 2010, Gale et al., 2017). A large body of research
suggests several multi-system, physiologic processes underlie
the pathogenesis of frailty syndrome and may explain its con-
tribution to cognitive impairment. For instance, it has been sug-
gested that chronic inflammation and immune activation con-
tribute to frailty via intermediary systems, including through
decreased musculoskeletal endocrine and cardiovascular hema-
tologic functioning (Chen et al., 2014). In turn, physiologic
dysregulation contributes to systematic decline (including de-
clines to brain functioning) that is thought to be manifested
through decreased muscle mass, strength, and power and
through slowed motor performance (Puts et al., 2005).
HIV, along with immune response to HIV disease, also has
direct effects on cognitive impairment, particularly towards the
later stages of the illness. In 2016, 35% of American PLWH
aged 50 years and older had acquired immunodeficiency syn-
drome (AIDS) (Prevention, 2018), and despite decreased inci-
dence of more severe forms of cognitive impairment (particu-
larly HIV-associated dementia) in the cART era (Heaton et al.,
2010), HIV-associated neurocognitive disorders (HAND)
(McArthur et al., 2004) as well as microglial activation or neu-
roinflammation generated by the HIV virus (Harezlak et al.,
2011) continue to persist. Among PLWH, it is estimated that
30% of individuals with asymptomatic HIV disease and 50%
with diagnoses of AIDS experience symptoms of mild
neurocognitive impairment (Heaton et al., 2011). Similar to
frailty syndrome, HAND has been linked to inflammatory
and immune dysfunction, which in part explain cognitive im-
pairment in this population (Cysique and Brew, 2009).
Recently, frailty’s effect on disease manifestation has been
reported in Alzheimer’s disease (AD). Through a cross-
sectional study, Wallace et al. (2019) found that frailty mod-
erated the relationship between AD disease pathology and
expression of AD dementia, such that low frailty resulted in
the absence of disease presentation even in people who al-
ready exhibited disease pathology. While frailty’s impact has
provided new insights in prevention and treatment within AD,
its effect on cognitive impairment among PLWH has been
relatively unexplored. To date, we know that cross-sectionally,
among PLWH, low frailty status is associatedwith the absence
of cognitive impairment in older adults (Wallace et al., 2017)
and that high frailty is associated with worse global
neurocognitive functioning, verbal fluency, executive func-
tioning, processing speed, and motor skills (Oppenheim
et al., 2018).
While these inter-individual correlations have been demon-
strated, the interaction of HIV and frailty on neurocognition
within the individual over time remains unknown.
Understanding cognitive vulnerabilities in the context of both
HIV and frailty may direct us towards possible neurobiologi-
cal processes of these combined conditions and ultimately
inform prevention and treatment. The present study seeks to
(1) examine the longitudinal change in neurocognitive func-
tioning by HIV serostatus and frailty status over a period of 2
years and to (2) explore cognitive domains most associated
with decline in the context of HIV and frailty. We hypothe-
sized that PLWH who were also frail would show the most
neurocognitive decline from baseline to 2-year follow-up
when compared to other groups.
Methods
Participants
Participants were 50 PLWH and 60 HIV-uninfected (HIV−)
individuals enrolled in the Multi-Dimensional Successful
Aging among HIV-Infected Adults study conducted at the
University of California, San Diego (UCSD) (Moore et al.,
2018, Rooney et al., 2019). All participants were aged 35 to
65 at baseline, consistent with study recruitment goals. The
current study is a secondary analysis on available longitudinal
frailty and neurocognitive data. Parent study exclusion criteria
were as follows: (1) presence of a neurological condition
known to impact neurocognitive functioning (e.g., stroke,
non-HIV neurological disorder), (2) history of head injury
with loss of consciousness or seizure disorder, (3) diagnosis
of a psychotic disorder or severe learning disorder (e.g.,
WRAT-4 Reading score < 70), and (4) positive urine toxicol-
ogy for illicit substances (excluding marijuana) on the day of
testing. Inclusion criteria for the current study were having
available frailty data at baseline and neurocognitive data at
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baseline and at the 2-year follow-up visit. All study proce-
dures were approved by the UCSD Institutional Review
Board. All participants were English-speaking and provided
written informed consent.
Participants were categorized into six groups based on
HIV status and baseline frailty status: HIV+/non-frail (n =
18), HIV−/non-frail (n = 39), HIV+/pre-frail (n = 25),
HIV−/pre-frail (n = 20), HIV+/frail (n = 7), and HIV
−/frail (n = 1). Because only one HIV− participant met
criteria for frailty at baseline, the HIV−/frail group was
not included in any statistical analyses.
Measures
Frailty status The fried frailty phenotype was used to deter-
mine physical frailty status for each participant (Fried et al.,
2001). Consistent with the fried frailty phenotype, five do-
mains of physical functioning were assessed, and deficits were
determined as follows: (1) unintentional weight loss (self-re-
ported ≥ 10 pounds lost in the past year), (2) weakness (< 20th
percentile of normative sample for grip strength, stratified by
sex and body mass index), (3) exhaustion (self-reported via
elevations on items 7 and 9 of the Center for Epidemiologic
Studies—Depression [CES-D] scale) (Lewinsohn et al.,
1997), (4) slow walking speed (< 20th percentile of normative
sample for total seconds to walk 15 feet, stratified by sex and
height), and (5) low physical activity (< 383 kcal/week for
men, < 270 kcal/week for women; self-reported via the
International Physical Activity Questionnaire) (Hallal and
Victora, 2004). Three frailty phenotypes were identified by
the number of symptoms met: frail (3 to 5 symptoms), pre-
frail (1–2 symptoms), and non-frail (0 symptoms). All partic-
ipants completed this frailty assessment at baseline, and most
(n = 96; 87%) completed it at the 2-year follow-up visit.
Neurocognitive functioningAll participants completed a stan-
dardized, comprehensive battery of neuropsychological tests
at baseline and at 2-year follow-up. This battery covered seven
domains of neurocognitive functioning: verbal fluency, exec-
utive functioning, processing speed, learning, delayed recall,
working memory, and motor skills. Details about this battery
have been published previously (Carey et al., 2004). Raw test
scores were converted to practice effect–corrected scaled
scores (M = 10, SD = 3 in normative samples) (Heaton
et al., 2004b, Norman et al., 2011). Scaled scores were not
corrected for demographics, as neurocognitive change is best
evaluated using neuropsychological test scores that do not
remove reliable sources of variance in change over time
(e.g., age). Scaled scores were averaged within each
neurocognitive domain to create domain-specific scaled
scores and were averaged across all tests to create a global
scaled score.
Everyday functioning and quality of life
Declines in instrumental activities of daily living (IADL) were
self-reported via a modified version of the Lawton and Brody
ADL questionnaire covering 11 IADL tasks (Heaton et al.,
2004a). Participants were asked to rate their current ability
to perform each task compared to their highest ability level
(i.e., when they were functioning “at their best”). For each
item, a decline was identified if participants reported being
less able to complete the activity independently (i.e., needing
more help) compared to their highest ability. The number of
reported declines was summed to obtain a total number of
IADL declines, with a possible range of 0 (no decline) to 11
(decline on all IADL items). Self-reported physical- and men-
tal health–related quality of life were assessed via the Medical
Outcomes Study Short-Form Health Survey (MOS SF-36).
Physical and mental health composite scores were calculated
via validated summary score formulas derived from an
obliquely rotated factor solution (Farivar et al., 2007).
Higher scores on these composites represent better health-
related quality of life.
Psychiatric and neuromedical diagnoses
The Composite International Diagnostic Interview (CIDI,
v2.1)(World Health Organization, 1998) is a structured,
computer-assisted interview that was administered to de-
termine the presence of current and lifetime major depres-
sive disorder (MDD) based on Diagnostic and Statistical
Manual of Mental Disorders—4th Edition (DSM-IV)
criteria. Participants also completed a comprehensive
medical history evaluation assessing for presence of four
cardiovascular conditions (i.e., hypertension, hyperlipid-
emia, congestive heart failure, and myocardial infarction)
known to be highly prevalent in frailty syndrome (Afilalo
et al., 2009, Newman et al., 2001). These conditions were
determined based on a combination of self-report (e.g.,
known diagnosis, taking medication for condition) and
laboratory measurements (i.e., blood pressure, blood pan-
el), and the number of cardiovascular conditions per par-
ticipant was summed. All participants were screened for
HIV infection using a fingerstick test (Medmira, Nova
Scotia, Canada) and confirmed with an Abbott RealTime
HIV-1 test (Abbott Laboratories, IL, USA) or by submit-
ting specimens to a Clinical Laboratory Improvement
Amendments (CLIA)-certified laboratory (ARUP
Laboratories, UT, USA) for HIV-1 viral load quantitation.
For participants with confirmed HIV infection, specific
HIV disease characteristics were evaluated (i.e., AIDS
status, plasma viral load, current and nadir CD4+ T-cell
counts, estimated duration of HIV disease, and current
antiretroviral therapy regimen).
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Statistical analyses
First, frequency of each frailty symptom was characterized in
each HIV serostatus group. Next, to compare demographic
and clinical characteristics between the six HIV/frailty groups,
one-way analysis of variance (ANOVA) or chi-squared anal-
ysis was used for continuous or dichotomous variables, re-
spectively. Non-parametric Wilcoxon tests were used for
non-normally distributed continuous variables (i.e., current
and nadir CD4 counts). Pairwise comparisons were made
using Tukey’s HSD (α = 0.05) for continuous outcomes or
Bonferroni adjustments (α = 0.05/6 = .008) for dichotomous
outcomes. Next, change in neurocognitive functioning over
time was examined separately by HIV status by the regression
of global scaled score on time in multigroup repeated mea-
sures models, with frailty status (i.e., non-frail, pre-frail, or
frail) as a grouping variable. That is, frailty status group-
specific parameters were estimated for change in
neurocognitive functioning over time among PLWH and
among HIV-uninfected individuals. These analyses were re-
peated for each of the seven neurocognitive domain scaled
score outcomes. This method provides an estimation of the
unstandardized beta (representing the change in
neurocognitive scaled score by unit of time [months]) for each
HIV/frailty status group, allowing us to examine whether
there was significant change in each group (i.e., significantly
different from 0). In order to account for the non-
independence of data due to repeated assessment, computa-
tion of standard errors was carried out using a sandwich esti-
mator. For any HIV/frailty status group that exhibited a statis-
tically significant decline in global or domain scaled scores,
three follow-up analyses were conducted: (1) Wald χ2 tests
were used to explore whether the observed decline was sig-
nificantly different from that of other frailty groups within
HIV serostatus, (2) the effect of individual frailty symptoms
(measured at baseline) on cognitive change was explored
using additional repeated measures models, and (3) the effect
of baseline cognitive score on cognitive change score (i.e.,
follow-up score minus baseline score) was examined within
HIV serostatus for cognitive domains with significant findings
using Pearson r correlation. Last, we examined whether there
were changes in frailty status from baseline to follow-up visit
and if these were related to changes in depressive symptoms
among PLWH, as this was relevant for our interpretation of
observed changes in neurocognition. Using one-way
ANOVA, PLWH who had stable frailty status were compared
to those who either improved (i.e., became less frail) or de-
clined (i.e., became more frail) by CES-D change score (i.e.,
follow-up CES-D minus baseline CES-D; positive values in-
dicate worsening depression). All descriptive analyses were
conducted using JMP Pro 12.0.1 (JMP Pro Version 12.0.1,
1989-2007), and all longitudinal analyses were conducted
using Mplus, version 7.4 (Muthén and Muthén, 1998-2012).
Results
Participant characteristics
Among PLWH, exhaustion was the most common frailty
symptom (66%), followed by low activity (53%), weight loss
(38%), slowness (19%), and weakness (16%). Among HIV−
participants, weakness was the most common frailty symptom
(52%), followed by low activity (28%), exhaustion (24%),
weight loss (14%), and slowness (10%). Demographic and
clinical characteristics of frailty status by HIV serostatus are
presented in Table 1. Education differed among groups, with
the HIV−/non-frail and HIV−/pre-frail having more years of
education than the HIV+/non-frail group (p < 0.04). No sig-
nificant differences in age, sex, race/ethnicity, or WRAT-4
Reading scores were noted among groups. Regarding neuro-
psychiatric characteristics, there were no differences in self-
reported current depression symptoms (CES-D total score) or
current DSM diagnosis of major depressive disorder (MDD)
among groups; however, there were significant differences in
lifetime DSM diagnosis of MDD (LT MDD). Regardless of
frailty status, PLWH had higher incidences of LT DSMMDD
compared to HIV− counterparts (p < 0.001). No difference in
the number of comorbid cardiovascular conditions was ob-
served among groups. Among PLWH, HIV disease character-
istics did not differ by frailty status.
Neurocognitive, everyday functioning,
and self-reported health problems among HIV/frailty
groups at baseline
Neurocognitive and everyday functioning data at baseline are
presented in Table 2. Generally, the HIV−/non-frail group
performed better on global, learning, recall, and motor do-
mains compared to the other groups. Specifically, the HIV
−/non-frail group had higher global functioning scores than
the HIV+/non-frail and HIV+/frail groups (p = 0.005), exhib-
ited better learning scores compared to all HIV+ groups (p <
0.001), and better recall scores compared to HIV+/non-frail
and HIV+/frail groups (p < 0.001). Similarly, motor function-
ing was worse among HIV+/pre-frail and HIV+/frail groups
compared to the HIV−/non-frail group (p = 0.003). Regarding
reported problems with instrumental activity of daily living
(IADL), the HIV+/frail group endorsed declines in signifi-
cantly more domains than all groups (p < 0.001). These results
were consistent with participant reported physical health qual-
ity of life (SF36 Physical Composite), where the HIV+/frail
group reported significantly worse physical health quality of
life than all other groups (p < 0.001).With regard to self-report
of mental health quality of life (SF36 Mental Health
Composite), the HIV+/pre-frail group reported worse mental
health than all other groups except for the HIV+/frail group (p
< 0.001). Tukey’s HSD pairwise comparisons also revealed
J. Neurovirol.
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that the difference in mental health quality of life between the
HIV+/frail group and the HIV−/non-frail group approached
statistical significance (p = 0.067).
Change in neurocognitive functioning from baseline
to 2-year follow-up
Within-person longitudinal analyses were completed to com-
pare cognitive outcomes by domain within HIV and frailty
subgroups from baseline to 2-year follow-up (see Table 3).
Within HIV+ groups, we found that individuals with pre-
frail status at baseline demonstrated significant global cogni-
tive decline at follow-up (B = − 0.029, SE = .014, p = 0.034),
exhibiting an estimated 0.7 unit decrease in global scaled
score over the entire 2-year period. This observed decline
among HIV+/pre-frail participants was marginally different
from the cognitive change observed among HIV+/non-frail
participants (Wald χ2 = 3.75, df = 1, p = 0.053) and not sta-
tistically different from that of HIV+/frail participants (Wald
χ2 = 1.24, df = 1, p = 0.265). None of the individual baseline
frailty criteria on their own were significant predictors of glob-
al cognitive change over time (ps > 0.05). In order to
Table 3 Change in cognitive
functioning (per month) from
baseline to year 2 follow-up in
people living with and without
HIV by frailty status
Number HIV+
(N = 50)
Number HIV−
(N = 60)
B SE p B SE p
Global
Non-frail 18 0.005 0.011 0.651 39 − 0.009 0.006 0.122
Pre-frail 25 − 0.029 0.014 0.034 20 − 0.013 0.006 0.050
Frail 7 − 0.002 0.020 0.934 1 – – –
Verbal fluency
Non-frail 18 0.018 0.016 0.268 39 0.014 0.009 0.117
Pre-frail 25 − 0.016 0.018 0.374 20 0.000 0.014 0.988
Frail 7 0.003 0.023 0.882 1 – – –
Executive functioning
Non-frail 18 0.014 0.017 0.423 39 − 0.001 0.010 0.902
Pre-frail 25 − 0.026 0.021 0.215 20 − 0.001 0.017 0.959
Frail 7 − 0.025 0.018 0.178 1 – – –
Processing speed
Non-frail 18 0.010 0.014 0.471 39 0.000 0.010 0.996
Pre-frail 25 − 0.047 0.022 0.031 20 − 0.027 0.011 0.011
Frail 7 0.006 0.025 0.809 1 – – –
Learning
Non-frail 18 − 0.013 0.023 0.573 39 − 0.033 0.016 0.045
Pre-frail 25 − 0.012 0.018 0.525 20 − 0.024 0.018 0.180
Frail 7 0.023 0.043 0.588 1 – – –
Delayed recall
Non-frail 18 0.006 0.024 0.792 39 − 0.032 0.015 0.029
Pre-frail 25 − 0.043 0.022 0.054 20 − 0.028 0.024 0.240
Frail 7 − 0.009 0.033 0.778 1 – – –
Working memory
Non-frail 18 − 0.007 0.016 0.683 39 0.007 0.016 0.656
Pre-frail 25 − 0.002 0.021 0.926 20 0.007 0.016 0.683
Frail 7 − 0.060 0.051 0.243 1 – – –
Motor skills
Non-frail 18 − 0.008 0.028 0.784 39 − 0.033 0.013 0.012
Pre-frail 25 − 0.048 0.023 0.038 20 − 0.013 0.018 0.457
Frail 7 0.056 0.046 0.223 1 – – –
Model estimates (B) reflect the change in cognitive scaled score per month over the 2-year study period.
Italicized p-values are significant at <0.05.
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determine whether the observed decline among HIV+/pre-
frail participants was possibly confounded by their relatively
higher baseline cognitive scores compared to other HIV+
groups, the relationship between baseline global cognitive
score and global change score was examined among all
PLWH in our sample. Baseline global score was not signifi-
cantly correlated with global change score among PLWH (r =
− 0.08, p = 0.63).
Examination of domain-specific cognitive changes re-
vealed that the HIV+/pre-frail group exhibited significant de-
clines in processing speed (B = − 0.047, SE = .022, p = 0.031)
and motor functioning (B = − 0.048, SE = .023, p = 0.038) and
a decline in delayed recall that approached statistical signifi-
cance (B = − 0.043, SE = .022, p = 0.054). The observed
decline in processing speed among the HIV+/pre-frail group
was significantly different from change among the HIV+/non-
frail group (Wald χ2 = 4.87, df = 1, p = 0.027), but not the
HIV+/frail group (p > 0.05). The observed decline in motor
functioning among the HIV+/pre-frail group was significantly
different from that among the HIV+/frail group (Wald χ2 =
4.11, df = 1, p = 0.043), but not from change among the HIV+/
non-frail group (p > 0.05). The marginal decline in delayed
recall among the HIV+/pre-frail group was not significantly
different from change among the HIV+/non-frail or HIV+/
frail groups (ps > 0.05). Additionally, none of the individual
baseline frailty criteria on their own were significant predic-
tors of decline in processing speed or motor functioning (ps >
0.05); however, baseline exhaustion predicted a decline in
delayed recall among PLWH (B = − 0.048, SE = .023, p =
0.041). Last, baseline processing speed score and baseline
motor score were not correlated with processing speed change
score (r = − 0.05, p = 0.79) or motor change score (r = − 0.18,
p = 0.28), respectively, among PLWH.
Among HIV− participants, the HIV−/pre-frail group also
seemed to decline in global function (B = − 0.013, SE = .006, p
= 0.050) and processing speed (B = − 0.027, SE = .011, p =
0.011). The observed decline in processing speed among the
HIV−/pre-frail group when compared to the HIV−/non-frail
group approached statistical significance (Waldχ2 = 3.32, df =
1, p = 0.069). Among all HIV− participants, baseline process-
ing speed score was not significantly correlated with process-
ing speed change score (r = − 0.17, p = 0.22). Notably, a
different pattern of decline emerged for other cognitive do-
mains among seronegative individuals. Specifically, the HIV
−/non-frail individuals also appeared to decline in cognitive
domains of learning (B = − 0.033, SE = .016, p = 0.045),
delayed recall (B = − 0.032, SE = .015, p = 0.029), and motor
functioning (B = − 0.033, SE = .013, p = 0.012). Wald χ2 tests
revealed that none of these observed declines among the HIV
−/non-frail group were significantly different than those of the
HIV−/pre-frail group (ps > 0.05). Among all HIV− individ-
uals, however, baseline scores in domains of learning, delayed
recall, and motor functioning were each significantly related
to respective change scores (learning: r = − 0.55, p < 0.01;
delayed recall: r = − 0.48, p < 0.01; motor: r = − 0.37, p <
0.01), indicating that participants with higher baseline scores
were more likely to show decline (i.e., a negative change
score) at follow-up.
It should also be noted that frailty status in some partici-
pants changed from baseline assessment to 2-year follow-up.
Out of all 96 participants with frailty status data at baseline
and follow-up, 70% (n = 67) had no change in frailty status
over the 2-year period, with 11% (n = 11) becoming more frail
and 19% (n = 18) becoming less frail. When examining
changes in frailty by HIV/frailty group, different patterns
emerge (Fig. 1). The HIV− and HIV+ non-frail groups
showed similar patterns such that 85% and 76%, respectively,
had no change in frailty status, and 15% and 24%, respective-
ly, declined from non-frail to pre-frail. Among the pre-frail
groups, 59% of HIV− and 61% of HIV+ persons had no
change in frailty status, 12% of HIV− and 0% of HIV+ per-
sons declined from pre-frail to frail, and 29% of HIV− and
39% of HIV+ improved from pre-frail to non-frail. Last, out of
only five HIV+/frail participants with follow-up frailty data,
76
85
61 59
20
24
15
12
39
29
80
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
HIV+/Non-frail
(n=17)
HIV-/Non-frail
(n=34)
HIV+/Pre-frail
(n=23)
HIV-/Pre-frail
(n=17)
HIV+/Frail
(n=5)
e
g
n
a
h
c
f
o
e
g
at
n
e
c
r
e
P
Stable Declined Improved
Fig. 1 Percentage of change in
frailty status from baseline to 2-
year follow-up by HIV/frailty
groups
J. Neurovirol.
one person (20%) had no change in frailty status while three
(60%) improved to pre-frail and one (20%) improved to non-
frail. Among the 45 PLWH who had frailty status character-
ized at both visits, CES-D change score (i.e., follow-up CES-
D minus baseline CES-D; positive values indicate worsening
depression) did not differ significantly by frailty stability (sta-
ble: M = − 2.1, SD = 15.6; improvers: M = 1.1, SD = 10.0;
decliners: M = 4, SD = 14.3; p = 0.64).
Given the fluctuation in frailty status from baseline to
follow-up among PLWH identified as pre-frail at baseline
(i.e., the group that showed the most consistent cognitive de-
clines), we examined likelihood of global cognitive decline
(i.e., a negative global change score) among HIV+/pre-frail
participants by frailty stability. That is we compared PLWH
who were stably pre-frail (n = 14) vs. PLWH who improved
from pre-frail to non-frail (n = 9). Logistic regression showed
a marginally statistically significant higher likelihood for the
stable pre-frail group to show global cognitive decline com-
pared to the group whose frailty status improved (OR = 12.0;
95% CI = 0.96–150.7; p = 0.054).
Discussion
This study uniquely examined within-person neurocognitive
change over 2 years by HIV and frailty status. We found that
PLWHwhowere pre-frail at baseline showed themost consistent
neurocognitive decline in global neurocognitive functioning, pro-
cessing speed, and motor skills, with a trend toward declining
delayed recall. Contrary to our hypotheses, our HIV+/frail group
did not demonstrate consistent declines in any neurocognitive
domain; however, this group was also not stable in frailty state
over time. Additionally, results showed no significant differences
in HIV characteristics among HIV+ groups at baseline. We also
interestingly found that the HIV−/non-frail group showed signif-
icant declines in learning, delayed recall, and motor skills; how-
ever, the decline observed among this group are likely driven by
their high baseline scores, making them more likely to decline
towards overall means (i.e., regression towards the mean)
(Nesselroade et al., 1980). Overall, the current findings highlight
the importance of examining pre-frailty as a clinical syndrome
among PLWH regardless of HIV disease severity and emphasize
the need for further longitudinal and intervention work to uncov-
er possible mechanisms for declines (or stability) found among
each HIV/frailty group.
Our findings suggest that pre-frailty may be an important
marker of risk for neurocognitive decline among PLWH. This
is further supported by additional analyses showing no asso-
ciation between baseline cognitive scores and cognitive
change scores among PLWH, suggesting that any observed
decline among the HIV+/pre-frail group was not simply due
to relatively higher baseline cognitive performance and regres-
sion toward the mean. The observed declines among pre-frail
PLWH are somewhat inconsistent with findings among sever-
al cross-sectional and longitudinal studies in the general pop-
ulation of older adults that show higher rates of cognitive
impairment and incident cognitive decline among individuals
with higher levels of frailty (Robertson et al., 2014, Robertson
et al., 2013). There may be several reasons for our unique
finding. First, HIVmay exhibit a different relationship to frail-
ty than other disease processes present in more general,
community-dwelling older adults without HIV, with different
subsequent effects on cognition. This is partly supported by
the different frequencies of frailty symptoms found between
HIV serostatus groups in our sample. Furthermore, HAND is
known to be relatively more stable compared to other age-
associated neurodegenerative disorders (e.g., Alzheimer’s dis-
ease [AD]) (Rubin et al., 2019). That is, while HIV disease
confers risk for developing mild cognitive impairment, having
a diagnosis of a mild form of HIV-associated neurocognitive
disorder does not predict progression to dementia (Clifford
and Ances, 2013). It may be that among PLWH, the interme-
diary pre-frail state is a marker of susceptibility to cognitive
decline, and that once this group ultimately reaches frail status,
the rate of cognitive decline flattens; however, longitudinal
data with more than two time points would be needed to sup-
port this hypothesis. Individuals in the HIV+/frail group also
qualitatively demonstrated the lowest baseline neurocognitive
scaled scores overall, possibly restricting their ability to de-
cline consistently as a group. Additionally, many of the PLWH
identified as frail at baseline improved to pre-frail or non-frail
status at the 2-year follow-up visit. Although reasons for this
reduction in frailty are unclear from our available data, their
improved physiological state was likely protective against
cognitive decline (Dufour et al., 2013). These changes in frail-
ty status may also suggest that frailty is more of a transitory
state among PLWHwho are of the ages included in our sample
(35 to 65 years). Last, we cannot rule out the possibility that
our lack of significant cognitive change findings among the
HIV+/frail group may be lost due to our small sample size (n =
7); thus, our findings in this group should be considered pre-
liminary until confirmed with a larger sample size.
The neurocognitive domains showing significant decline
among the HIV+/pre-frail group (i.e., processing speed and
motor skills) are consistent with domains commonly affected
in HIV (Heaton et al., 2011). The neurobiological mechanisms
proposed to contribute to such neurocognitive deficits in the
context of HIV include a cascade of neuroinflammatory
events that lead to synaptodendritic injury and neuronal apo-
ptosis particularly in subcortical structures (e.g., striatum)
(Cody and Vance, 2016, Moore et al., 2006). Furthermore,
these HIV-related central nervous system injuries are hypoth-
esized to be exacerbated by health conditions also associated
with increased levels of frailty (e.g., vascular co-pathology,
aging-related immunological senescence, poor nutrition)
(Robertson et al., 2013, Valcour et al., 2004), suggesting
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possible overlapping factors underlying the link between frail-
ty and cognition among PLWH. Notably, the observed de-
clines in processing speed and motor skills among pre-frail
PLWH are inconsistent with literature describing
community-dwelling populations without HIV, where memo-
ry has been demonstrated to be most associated with frailty
syndrome (Brigola et al., 2015). Among non-HIV popula-
tions, recent research suggests AD pathology as a potential
mechanism linking frailty and cognition (Buchman et al.,
2007, Wallace et al., 2019), which initially targets the neuro-
anatomical networks of memory. Our discrepant findings pro-
vide additional evidence that the relationship between frailty
and cognition among PLWH may be driven by different
neurobiologic mechanisms than those mechanisms found
among other clinical populations such as individuals with AD.
Similar to the pattern noted above, the HIV−/pre-frail
group also demonstrated a significant decline in processing
speed, with a trending decline in global functioning.
Although it is possible that HIV−/frail individuals may also
have declines within these domains, we were unable to ad-
dress this as we had only one individual that met our inclusion
criteria for this group. Interestingly, we found the HIV−/non-
frail group demonstrated significant declines in learning, de-
layed recall, and motor skills. Whereas declines within mem-
ory subtypes (learning and delayed recall) are expected as
HIV− persons age, we certainly did not expect these findings
for only the non-frail group due to the known research about
the relationship between higher levels of frailty and risk for
cognitive decline in HIV− older adult populations (Boyle
et al., 2010b, Buchman et al., 2007). The post-hoc analysis
examining the association between baseline scores and change
scores among HIV− participants, however, revealed that
higher baseline scores related to greater declines at follow-
up, which is consistent with the statistical concept of regres-
sion toward the mean (Nesselroade et al., 1980). Given that
the HIV−/non-frail group had the highest baseline scores in
domains of learning, delayed recall, and motor skills, they
may have simply been statistically more likely to show de-
clines at the follow-up visit. Still, we certainly cannot rule out
possible underlying biological or physiological processes
(e.g., neuroinflammation, neuropathology indicative of neuro-
degeneration) occurring in this group that are not captured by
frailty status and our other available data (i.e., demographics,
psychiatric factors, comorbid cardiovascular conditions).
Importantly, the comparisons of baseline neurocognitive
scores by HIV/frailty group show that global functioning,
learning, delayed recall, and motor skills are worst among
those who are frail, consistent with much of the current
cross-sectional research on frailty and cognition among indi-
viduals with and without HIV (Oppenheim et al., 2018,
Robertson et al., 2014). This also highlights an important dis-
tinction between cross-sectional and longitudinal findings.
That is, although a cross-sectional analysis of baseline
neurocognitive functioning by group suggested that frail
PLWHwere most vulnerable to neurocognitive deficits, our lon-
gitudinal analyses showed that our frail PLWH were not stably
frail and were therefore not as high risk for cognitive decline as
initially thought. In contrast, our longitudinal analyses identified
pre-frail PLWH (especially stably pre-frail PLWH) as most vul-
nerable to neurocognitive decline. While inter-individual vari-
ability is often assumed to apply to within-individual risk for
change over time, our findings violate this assumption and high-
light a significant study design strength.
In considering mechanisms that may underlie the link be-
tween frailty status and cognitive decline among PLWH, one
hypothesis might consider the role of HIV disease characteris-
tics, as certain markers (e.g., nadir CD4, viral load detectability)
are known to be related to HIV-associated neurocognitive im-
pairment (Heaton et al., 2010). In our sample, however, HIV
disease characteristics did not differ between frailty status
groups, decreasing the likelihood that these markers of HIV
disease were mediating factors. Current depressive symptoms
have also repeatedly demonstrated to be independently worse in
PLWH and frailty syndrome (Rabkin, 2008, Soysal et al.,
2017). Although we did not observe differences in current
MDD diagnoses or self-reported symptoms of depression
(CES-D), we did see that PLWH reported significantly higher
rates of lifetime MDD. Additional analyses showing that
changes in frailty were not associated with changes in CES-D
score, however, suggest that depressive symptomology did not
significantly impact frailty status among PLWH.
This is the first study, to our knowledge, to examine longi-
tudinal change in neurocognitive functioning by HIV and
frailty status. Thus, a discussion of our limitations is necessary
for future work to build upon the current report. First, our
sample size was limited, especially within frail groups. This
can be explained by the nature of our study, which required
participants to be physically able to travel and sit-through
extensive evaluations. While we had enough HIV+/frail par-
ticipants for statistical model estimation, we were not able to
estimate cognitive change in the HIV−/frail group. Our small
sample size also limited our ability to adjust for covariates in
the model, and thus, we do not know whether certain partic-
ipant characteristics may explain the relationship between
frailty and cognition; however, our results are supported by
the fact that there were no differences in demographic/clinical
characteristics within each serostatus group by frailty status.
Additionally, most HIV+ participants who were identified as
frail at baseline improved frailty status by follow-up, limiting
our ability to examine only individuals who were stably frail.
Although this may be related to the relatively young age of
some individuals in our sample, previous work has shown that
it is relevant to include younger PLWH in frailty work
(Oppenheim et al., 2018). Future studies would benefit from
specifically recruiting for individuals in each HIV/frailty
group. Next, although identifying frailty using the Fried
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criteria is clinically relevant, it is possible that other, more
comprehensive operationalizations of frailty (e.g., deficit ac-
cumulation index) (Rockwood and Mitnitski, 2007) may in-
crease sensitivity in detecting vulnerability to cognitive
change among PLWH. Last, longer-term follow-up will be
necessary to further understand trajectories of decline (linear
or non-linear) or markers of stability in HIV/frailty groups.
In summary, our findings suggest that pre-frail PLWH
(especially thosewho are stably pre-frail) are vulnerable to global
neurocognitive decline and decline in the specific cognitive do-
mains of processing speed, motor skills, and possibly delayed
recall. Interventions to reduce and prevent frailty syndromes
among PLWH could help improve and maintain optimal
neurocognitive function in this at-risk population. Specifically,
interventions that include a group physical activity component
seem to be the most effective in reducing frailty among
community-dwelling older adults (Puts et al., 2017, Montoya
et al., 2019). Additionally, improving positive psychosocial fac-
tors may be another viable frailty prevention method among
PLWH (Rubtsova et al., 2018); however, at this time, efficacy
of such frailty interventions among PLWH is unknown. Further
understanding biopsychosocial risk factors associated with frailty
and neurocognitive decline among PLWH are needed in order to
develop appropriate and effective interventions.
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